ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.852,26
0,90%
Brent Oil
84,85
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) Notícias

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEM
DataHoraFonteTítuloCódigoCompanhia
05/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202418:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
03/06/202409:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
01/06/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202409:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202418:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202417:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202408:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202407:42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202407:40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202417:05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
08/05/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
06/05/202417:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202411:09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202408:00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202407:59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
14/03/202408:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
01/03/202409:00GlobeNewswire Inc.Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaNASDAQ:CGEMCullinan Therapeutics Inc
27/02/202410:00GlobeNewswire Inc.Cullinan Oncology to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
14/02/202423:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGEMCullinan Therapeutics Inc
08/01/202418:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
18/12/202318:53GlobeNewswire Inc.Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
14/12/202318:30GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesNASDAQ:CGEMCullinan Therapeutics Inc
08/11/202309:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202309:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
03/11/202313:01GlobeNewswire Inc.Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023NASDAQ:CGEMCullinan Therapeutics Inc
10/08/202308:00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
09/08/202308:00GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNASDAQ:CGEMCullinan Therapeutics Inc
03/08/202317:15PR Newswire (US)REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsNASDAQ:CGEMCullinan Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEM

Seu Histórico Recente

BIT
UC8HRY
Unicredit Bank
USOTC
USDC
Usdata (CE)
NASDAQ
VTRXX
Jpmorgan Treasury Plus MM Fund
BIT
UC7EZ4
Unicredit Bank
BIT
UC59X4
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados